[Advanced non-small cell lung cancer - pioneer in personalized oncology].
| Autor: | Saalfeld FC, Aust DE, Wermke M |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2023 Sep; Vol. 148 (18), pp. 1166-1173. Date of Electronic Publication: 2023 Sep 01. |
| DOI: | 10.1055/a-1935-1939 |
| Abstrakt: | In no other cancer is clinical practice as close to the ideals of personalized oncology as in the treatment of non-small cell lung cancer (NSCLC). Here, we briefly outline the basic principles of molecular analysis. The focus of the article is on the clinical utility of targeted therapy. Finally, we highlight the challenges for medical staff and structural solutions reflecting the situation in Germany. Competing Interests: Wermke, M Honorare: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT TUD, Amgen, Novartis. Beratung: Bristol-Myers Squibb, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, Immatics, Bayer, ImCheck Therapeutics. Forschungsförderung: Roche. Reisekosten/Unterbringung: Pfizer, Bistol-Myers Suqibb, AstraZeneca, Amgen, GEMoaB, Sanofi/Aventis, Immatics, Merck Serono Aust, DE Honorare: Roche, Astra Zeneca, MSD, Pfizer, Novartis Saalfeld, FC Honorare: AstraZeneca, Novarits, Pfizer, Takeda. Beratung: AstraZeneca, Janssen. Reisekosten/Unterbringung: Lilly, Takeda (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|